← Leaderboards
Lisa M Frenkel
University Of Washington
$29,105,317
Attributed
$36,819,381
Total exposure
29
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$36,819,381 · 29
By mechanism
R01$31,030,288 · 12
T32$2,169,971 · 1
U01$1,449,287 · 1
R21$1,260,404 · 3
R56$606,075 · 1
M01$173,871 · 9
Top collaborators
- Corey Casper5 shared
- Paul K Drain5 shared
- Geoffrey Scott Gottlieb5 shared
- Linos Vandekerckhove5 shared
Most similar at University Of Washington
Same institution · by research overlap
- Grace C John-Stewart$42,921,726
- Robert W. Coombs$29,428,054
- Joanne Donna Stekler$9,601,472
- Ann Marie Kimball$2,279,704
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionDrug ResistanceViralHiv InfectionsAdultVirusSpecimenWomanCellsHiv-1BloodBaseAnti-Retroviral AgentsVariantCd4 Positive T LymphocytesAntiretroviral TherapyInnovationPlasmaHuman SubjectMutationAntiviral AgentsCommunitiesChildPharmaceutical Preparations
Grant awards (92)
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$780,602
R01 · FY2023 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$1,219,140
R01 · FY2022 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$819,182
R01 · FY2021 · AI · contact PI
Defining HIV reservoirs that rebound following suspension of ART$725,815
R01 · FY2021 · AI · contact PI
Mechanisms controlling the persistence of infectious HIV reservoirs in children$564,187
R01 · FY2021 · HD · contact PI
HIV integration-mediated modulation of immune regulation in HPV-associated cancers$1,365,545
R01 · FY2020 · CA · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$834,531
R01 · FY2020 · AI · contact PI
Defining HIV reservoirs that rebound following suspension of ART$785,807
R01 · FY2020 · AI · contact PI
Mechanisms controlling the persistence of infectious HIV reservoirs in children$643,772
R01 · FY2020 · HD · contact PI
Immune responses to HSV-2 recurrence replenish HIV tissue reservoirs during ART$478,209
R01 · FY2020 · AI · contact PI
HIV integration-mediated modulation of immune regulation in HPV-associated cancers$1,423,275
R01 · FY2019 · CA · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$900,704
R01 · FY2019 · AI · contact PI
Mechanisms controlling the persistence of infectious HIV reservoirs in children$768,168
R01 · FY2019 · HD · contact PI
Defining HIV reservoirs that rebound following suspension of ART$726,094
R01 · FY2019 · AI · contact PI
Academic Pediatric Infectious Disease$286,092
T32 · FY2019 · HD · contact PI
HIV integration-mediated modulation of immune regulation in HPV-associated cancers$1,434,093
R01 · FY2018 · CA · contact PI
Defining HIV reservoirs that rebound following suspension of ART$750,560
R01 · FY2018 · AI · contact PI
Mechanisms controlling the persistence of infectious HIV reservoirs in children$695,642
R01 · FY2018 · HD · contact PI
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART$453,349
R01 · FY2018 · AI · contact PI
Academic Pediatric Infectious Disease$274,981
T32 · FY2018 · HD · contact PI
Defining HIV reservoirs that rebound following suspension of ART$829,247
R01 · FY2017 · AI · contact PI
HIV integration-mediated modulation of immune regulation in HPV-associated cancers$622,563
R01 · FY2017 · CA · contact PI
Mechanisms controlling the persistence of infectious HIV reservoirs in children$504,787
R01 · FY2017 · HD · contact PI
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART$453,349
R01 · FY2017 · AI · contact PI
HIV integration-mediated modulation of immune regulation in HPV-associated cancers$692,917
R01 · FY2016 · CA · contact PI
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART$453,349
R01 · FY2016 · AI · contact PI
Academic Pediatric Infectious Disease$227,927
T32 · FY2016 · HD · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$472,143
R01 · FY2015 · AI · contact PI
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART$453,349
R01 · FY2015 · AI · contact PI
Academic Pediatric Infectious Disease$266,260
T32 · FY2015 · HD · contact PI
Drug-resistance testing in Kenya to improve ART suppression of HIV replication$1,347,525
R01 · FY2014 · AI · contact PI
A rapid point-of-treatment diagnostic assay for HIV-resistance to 1st-line ART$497,126
R01 · FY2014 · AI · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$472,549
R01 · FY2014 · AI · contact PI
Academic Pediatric Infectious Disease$282,647
T32 · FY2014 · HD · contact PI
Drug-resistance testing in Kenya to improve ART suppression of HIV replication$780,108
R01 · FY2013 · AI · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$444,565
R01 · FY2013 · AI · contact PI
Academic Pediatric Infectious Disease$277,930
T32 · FY2013 · HD · contact PI
Drug-resistance testing in Kenya to improve ART suppression of HIV replication$934,685
R01 · FY2012 · AI · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$473,325
R01 · FY2012 · AI · contact PI
Academic Pediatric Infectious Disease$95,277
T32 · FY2012 · HD · contact PI
Academic Pediatric Infectious Disease$148,420
T32 · FY2011 · HD · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$17,587
R01 · FY2011 · AI · contact PI
HIV-1 evolution in the female genital tract and trafficking to the blood$606,075
R56 · FY2010 · AI · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$422,576
R01 · FY2010 · AI · contact PI
Academic Pediatric Infectious Disease$310,437
T32 · FY2010 · HD · contact PI
Quantification and dynamics of HIV-1 drug resistant mutants by pirosequencing$248,913
R21 · FY2010 · AI · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$377,774
R01 · FY2009 · AI · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$345,879
R01 · FY2009 · AI · contact PI
Reservoirs of drug-resistant HIV-1$344,481
R01 · FY2009 · AI · contact PI
Reservoirs of drug-resistant HIV-1$304,169
R01 · FY2009 · AI · contact PI
Quantification and dynamics of HIV-1 drug resistant mutants by pirosequencing$300,605
R21 · FY2009 · AI · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$386,237
R01 · FY2008 · AI · contact PI
Reservoirs of drug-resistant HIV-1$345,818
R01 · FY2008 · AI · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$395,101
R01 · FY2007 · AI · contact PI
Reservoirs of drug-resistant HIV-1$303,620
R01 · FY2007 · AI · contact PI
Reservoirs of drug-resistant HIV-1$91,306
R01 · FY2007 · AI · contact PI
PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)$4,661
M01 · FY2007 · RR · contact PI
PACTG 1055: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV -INFECTED CHILDREN$3,191
M01 · FY2007 · RR · contact PI
ASSESSMENT OF ALVEOLAR MACROPHAGES AS A RESERVOIR FOR HIV$1,716
M01 · FY2007 · RR · contact PI
Mechanism/predictors of genital/rectal HIV shedding during ART w/plasma <50c/mL$448,980
R01 · FY2006 · AI · contact PI
Reservoirs of drug-resistant HIV-1$314,602
R01 · FY2006 · AI · contact PI
Immunization by HIV exposure during chemoprophylaxis$292,132
R01 · FY2006 · HD · contact PI
Etiology of mastitis in HIV-1 infected women$256,658
R21 · FY2006 · AI · contact PI
PACTG 1055: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV -INFECTED CHILDREN$30,019
M01 · FY2006 · RR · contact PI
ASSESSMENT OF ALVEOLAR MACROPHAGES AS A RESERVOIR FOR HIV$27,712
M01 · FY2006 · RR · contact PI
PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)$18,477
M01 · FY2006 · RR · contact PI
Reservoirs of drug-resistant HIV-1$316,171
R01 · FY2005 · AI
Etiology of mastitis in HIV-1 infected women$225,000
R21 · FY2005 · AI
ASSESSMENT OF ALVEOLAR MACROPHAGES AS A RESERVOIR FOR HIV$33,495
M01 · FY2005 · RR
PEDIATRIC LATE OUTCOMES AIDS CLINICAL TRIAL GROUP # 219$12,886
M01 · FY2005 · RR
Reservoirs of drug-resistant HIV-1$229,228
R21 · FY2004 · AI
Pediatric Late Outcomes (ACTG 219)$22,394
M01 · FY2004 · RR
Prevention of HIV resistance to nevirapine in pregnancy$41,805
R03 · FY2003 · TW
THERAPY EFFECTS ON HIV 1 POPULATION DYNAMICS IN CHILDREN$409,340
R01 · FY2002 · HD
AIDS CLINICAL TRIALS$272,314
U01 · FY2002 · AI
Prevention of HIV resistance to nevirapine in pregnancy$43,840
R03 · FY2002 · TW
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2002 · RR
HIV SHEDDING AND EVOLUTION$0
P01 · FY2002 · HD
HIV SHEDDING AND EVOLUTION$0
P01 · FY2002 · HD
AIDS CLINICAL TRIALS$593,618
U01 · FY2001 · AI
THERAPY EFFECTS ON HIV 1 POPULATION DYNAMICS IN CHILDREN$397,417
R01 · FY2001 · HD
Immunization by HIV exposure during chemoprophylaxis$324,912
R01 · FY2001 · HD
Prevention of HIV resistance to nevirapine in pregnancy$43,840
R03 · FY2001 · TW
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2001 · RR
AIDS CLINICAL TRIALS$583,355
U01 · FY2000 · AI
THERAPY EFFECTS ON HIV 1 POPULATION DYNAMICS IN CHILDREN$391,924
R01 · FY2000 · HD
PHASE II EVALUATION ON ZDV 3TC VS D4T RITONAVIR VS ZDV 3TC RITONAVIR$3,864
M01 · FY2000 · RR
HIV 1 DYNAMICS &RESISTANCE IN CHILDREN GIVEN HIGHLY ACTIVE ANTIRETRO$3,864
M01 · FY2000 · RR
HIV 1 DYNAMICS &RESISTANCE IN CHILDREN GIVEN HIGHLY ACTIVE ANTIRETRO$3,864
M01 · FY2000 · RR
PHASE II EVALUATION ON ZDV 3TC VS D4T RITONAVIR VS ZDV 3TC RITONAVIR$3,864
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL--ACTG219$3,864
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2000 · RR